Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance

Cytek Biosciences, Inc.

Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).
Installed base 3,789 instruments (+125 units); TTM recurring revenue 35% of total (up from 31%).
GAAP net loss $18.9M vs $11.4M; adjusted EBITDA loss $9.1M vs $3.3M loss.
G&A expenses up 43% YoY driven by litigation, consulting, and bad debt reserves.
Reaffirms FY2026 revenue guidance $205M-$212M (2-5% growth).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Cytek Biosciences, Inc. reported first quarter ended March 31, 2026 results: revenue $44.1 million, net income Net loss in the first quarter of 2026 was $18.9 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $44.1 million
Net income: Net loss in the first quarter of 2026 was $18.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025 • Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to

View on SEC.gov

Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.